Daniel Collins
Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.
More From Daniel Collins
Analyzing CARA, INSY, and GWPH’s Earnings Trends
GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.
CARA, INSY, and GWPH: Analysts’ Recommendations in January
On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.
Marijuana Stock iAnthus Capital Already Up ~23% in January
Today, on the OTC markets, iAnthus Capital Holdings stock (ITHUF) is trading ~3.63% above yesterday’s closing price of $4.84.
Charlotte’s Web Holdings’ Stock Grew ~11% Last Week
On January 25, Charlotte’s Web Holdings’ (CWBHF) stock price closed at $14.41, ~4.87% higher than its closing price of $13.74 on January 24 and ~11% higher than its closing price of $6.21 on January 18.
CannTrust Holdings’ Stock Grew ~11% Last Week
On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.
Innovative Industrial Properties’ Stock Grew ~10% Last Week
On January 25, Innovative Industrial Properties (IIPR) stock price closed at $59.94, ~3.52% higher than its closing price of $57.90 on January 24 and ~10% higher compared than its closing price of $54.32 on January 18.
Why Auxly Cannabis Group Stock Grew ~6.75% on January 25
On January 25, on the OTC markets, Auxly Cannabis Group’s stock price closed at $0.72, which is ~6.75% higher than its close of $0.67 on January 24 and reflects ~8% growth YTD (year-to-date).
FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%
Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.
Which Cannabis Stocks Were in the Green on January 24?
On January 24, Cannabis Strategic Ventures stock closed at $1.69—an ~8.33% rise compared to its closing price of $203.66 on January 23.
Cara Therapeutics: Earnings Trends and Recent Developments
In the first nine months of 2018, Cara Therapeutics (CARA) reported a net income and EPS of -$53.4 million and -$1.54, respectively.
Cara Therapeutics: A Financial Overview in January
In the first nine months of 2018, Cara Therapeutics (CARA) generated revenues of $7.9 million.
Cara Therapeutics Has Risen ~18% in January
Cara Therapeutics’ (CARA) stock price reached $15.35 on January 18—compared to $13.00 when the market closed on December 31.
Johnson & Johnson Releases Its 2018 Results: Revenue Up 6.7%
Today, Johnson & Johnson (JNJ) released its fourth-quarter and 2018 financial results.
BC Supreme Court Approves iAnthus and MPX’s Deal
On January 18, iAnthus Capital Holdings stock closed at $4.7, ~5.18% higher than its close of $4.5 on January 17, 2019.
Charlotte’s Web Holdings Stock Has Already Risen ~18% in January
Charlotte’s Web Holdings reached $13.04 on January 18, which represents an ~18% YTD increase.
Aptinyx Stock Plunged 70% after Clinical Trial Failure
Today, Aptinyx (APTX) is trading at $5.26, which is a ~70.5% decline from yesterday’s closing price of $17.83.
Boston Scientific and Edward Lifesciences Settle Patent Dispute
Today, Boston Scientific (BSX) is trading at $36.76, which is a ~4.11% increase from yesterday’s closing price.
How Is Green Thumb Industries Financially Positioned in January?
Green Thumb Industries reported net revenue of $17.17 million in the third quarter of 2018. What do analysts expect for the fourth quarter?
GTBIF Acquires Advanced Grow Labs and Enters Connecticut Market
In January, Green Thumb announced that it had entered into a definitive agreement to acquire Advanced Grow Labs for a value of $80.0 million.
Green Thumb Industries Has Already Risen ~50% in January
On January 11, Green Thumb Industries (GTBIF) stock closed at $12.05, up ~15% from its previous week’s closing price.
How INSYS Therapeutics’ Earnings Were Trending
In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively.
How Is INSYS Therapeutics Financially Positioned in January?
In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.
Cannabis Stock INSYS Therapeutics Has Risen 28% in January
On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.
Here Are Some of GW Pharmaceuticals’ Key Growth Drivers
GW Pharmaceuticals completed three phase 3 trials in Europe with Sativex (nabiximos), which all produced positive results.
How GW Pharmaceuticals’ Earnings Are Trending
In fiscal 2018, GW Pharmaceuticals (GWPH) reported net income and EPS of -$295.2 million and -$0.88, respectively.
A Look into GW Pharmaceuticals’ Revenue Trends
In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.
GW Pharmaceuticals Has Already Soared 23% in January
GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products.
Why Globus Medical Stock Rose 10% on January 9
On January 9, Globus Medical was trading at a stock price of $43.79, which is an ~9.91% rise from its closing price of $39.84 on January 8.
CannTrust Holdings: Analysts Are Mainly Positive in January
On January 8, CannTrust Holdings’ (CNTTF) stock price closed at $5.63, which is ~3.04% growth from its close of $5.47 on January 7.
Auxly Cannabis: Business Strategies and Financial Projections
Analysts expect Auxly Cannabis to report a net income of -40.08 million Canadian dollars in fiscal 2018.
Auxly Cannabis: Analyzing the Stock Performance
Auxly Cannabis’ stock price closed at $0.67 on January 7, which is ~52% growth from its 52-week low of $0.44 on December 24.
Why CRISPR Therapeutics Stock Rose ~13.05% Yesterday
On January 7, CRISPR Therapeutics stock rose ~13.05% to $34.22 from its previous close of $30.27 on January 4.
Why Neurocrine Biosciences Stock Rose 9.6% Yesterday
On January 7, Neurocrine Biosciences (NBIX) stock rose ~9.57% to reach $81.86 from its prior close of $74.71.
How Is Sarepta Therapeutics Positioned in January?
In the first nine months of 2018, Sarepta Therapeutics’ net revenues grew ~123% YoY to reach $216.6 million from $97.3 million.
A Look at Sarepta Therapeutics’ Recent Developments
In the first nine months of 2018, Sarepta Therapeutics’ (SRPT) net income and EPS amounted to -$221.0 million and -$3.38, respectively, compared to -$26.7 million and -$0.47 in the same period the prior year.
Sarepta Therapeutics Stock Rose 96% in 2018
On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.
Sage Therapeutics: Results from the Phase 3 ROBIN Trial
On January 7, Sage Therapeutics presented the results of the Phase 3 ROBIN trial. SAGE-217 met the clinical trial’s primary and secondary endpoints.
Why Portola Pharmaceuticals Rose 8.09% on January 4
On January 4, Portola Pharmaceuticals stock closed at $19.38, an ~8.09% increase from its prior close of $17.93 on January 3,
Why Epizyme Stock Rose ~33% on January 4
Of the ten analysts tracking Epizyme in January, four of them recommend a “strong buy,” while another four analysts recommend a “buy.”
What to Expect from BMY’s Celgene Acquisition
The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.
Bristol-Myers Squibb to Acquire Celgene
Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.
Let’s Talk about Bristol-Myers Squibb’s 2019 EPS Guidance
Today, Bristol-Myers Squibb (BMY) is trading at $45.85, ~11.86% lower than its previous day’s closing price.
How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
A Financial Overview of Sangamo Therapeutics in December 2018
In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.
Why Tandem Diabetes Care Stock Soared Over 1,480% in 2018
Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.
Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.
Spectrum Pharmaceuticals: Financial Overview in December
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.
A Financial Overview of Teva Pharmaceutical in December
In the first nine months of 2018, Teva Pharmaceutical’s net revenue fell 16% YoY (year-over-year) to $14.3 billion from $17.0 billion.
Teva Pharmaceutical Stock Rose More than ~8% on December 26
On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24.
Pfizer’s Prevnar 13 and Other Developments
Pfizer’s (PFE) Prevnar (or Prevenar) 13 is used to prevent pneumococcal diseases.
Pfizer’s Vaccines: A Look at Their Market Performance
In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.
Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth
In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million.
How Pfizer’s Sutent and Xalkori Have Performed
In the first nine months of this year, Pfizer’s (PFE) Sutent sales fell 2% YoY (year-over-year) to $785.0 million from $805.0 million.
This Drug Is Expected to Be a Significant Driver for Pfizer
In the first nine months of this year, Pfizer’s (PFE) Ibrance revenue grew 24% YoY (year-over-year) to $3.0 billion from $2.4 billion.
Pfizer and GlaxoSmithKline’s Joint Venture: What to Expect
The new joint venture between GlaxoSmithKline and Pfizer will enable GlaxoSmithKline to strengthen its consumer healthcare business.
Pfizer and GlaxoSmithKline’s Consumer Health Business
Pfizer’s (PFE) consumer health business generated revenues of $2.6 billion during the first nine months in 2018.
Pfizer and GlaxoSmithKline Form a Joint Venture
On December 19, GlaxoSmithKline (GSK) and Pfizer (PFE) entered into an agreement to combine both of their consumer health businesses.
Why Allergan Stock Fell 7% Today
Allergan (AGN) is trading at $135.98, which is a ~7.47% decline from its close of $146.76 on December 18.
Pfizer’s Stock Performance and Earnings Trends
On December 17, Pfizer’s stock price closed at $43.11, which is an ~1.58% decline from its close of $43.80 on December 14.
Analyzing Pfizer’s Revenues in December
Pfizer’s net revenues were $39.7 billion in the first nine months of 2018—compared to $38.8 billion during the same period in 2017.
Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.
Why Neurocrine Biosciences Stock Is Plummeting Today
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11.
How Did Medtronic’s Restorative Therapies Group Perform?
Medtronic’s (MDT) Spine Therapies generated revenues of $1.3 billion in the first half of fiscal 2019.
How Does Medtronic’s Restorative Therapies & Diabetes Group Look?
Medtronic’s Restorative Therapies Group consists of Spine, Brain, Specialty and Pain therapies.
How Medtronic’s Minimally Invasive Therapies Group Has Performed
Medtronic’s MITG segment generated revenues of $4.1 billion in the first half of fiscal 2019 compared to $4.4 billion in the first half of fiscal 2018.
A Look at Medtronic’s Cardiac & Vascular Group’s Revenue Streams
Medtronic’s (MDT) Cardiac Rhythm & Heart Failure segment generated revenues of $1.47 billion in the second quarter of fiscal 2019.
How Medtronic’s Cardiac and Vascular Group Performed
Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018.
A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.
How Wall Street Analysts View Medtronic in December
Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”
Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.
Bausch’s Ultra Multifocal Contact Lenses Get FDA Approval
On December 5, Bausch + Lomb announced that the FDA approved its Ultra multifocal contact lenses for patients with astigmatism.
GlaxoSmithKline Agreed to Acquire Tesaro
On December 3, GlaxoSmithKline (GSK) entered into an agreement with Tesaro (TSRO). GlaxoSmithKline will acquire Tesaro for ~$5.1 billion.
Why Clovis Oncology Stock Rose 48% in November
On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.
Why Exelixis Stock Soared 46% in November
Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.
IQVIA Stock Has Increased 36% in 2018
On November 29, IQVIA Holdings’ (IQV) stock price closed at $124.95, which is ~6% growth from its close of $117.73 on November 23.
Express Scripts Holding Stock Has Risen 36% in 2018
On November 29, Express Scripts Holding’s stock price closed at $101.22, which is ~5% growth from the close of $96.81 on November 23.
United Health Group Stock Has Risen 28% in 2018
On November 29, United Health Group’s (UNH) stock price closed at $282.55, which is ~8% growth from its close of $261.62 on November 23.
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.
Illumina Stock Has Jumped 45% Year-to-Date
On November 26, Illumina (ILMN) stock closed at $316.79, a rise of ~2.03% from its previous close of $310.50 on November 23.
A Closer Look at Dexcom Stock’s 117% Year-to-Date Growth
On November 23, Dexcom (DXCM) stock closed at $124.28, a rise of ~2.20% from its previous day’s close of $121.61.
Why Analysts Are Mostly Positive on Boston Scientific Stock
Boston Scientific stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23.
Intuitive Surgical Stock Has Seen Growth of 34% Year-to-Date
Intuitive Surgical’s stock price rose from $364.94 at the close of market on December 29, 2017, to $489.57 on November 23, 2018.
Tandem Diabetes Care Stock Has Skyrocketed in 2018
On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.
Mirati Therapeutics Stock Has Delivered Solid Growth in 2018
On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.
Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date
On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30.
Endocyte Stock Has Seen a Solid Hike in 2018
Endocyte (ECYT) stock rose from $4.28 at the close of market on December 29, 2017, to $23.60 at the close of market on November 20, 2018.
United Therapeutics: Recent Developments and Analysts’ Ratings
On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).
Why Has AstraZeneca’s Stock Price Increased in 2018?
On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.
GlaxoSmithKline Stock Has Increased ~15% in 2018
On November 19, GlaxoSmithKline’s stock price closed at $40.83, which represents ~1.21% growth from its close of $40.34 on November 16.
Analyzing Eli Lilly’s Stock Price and Financial Performance
On November 16, Eli Lilly’s (LLY) stock price closed at $113.83, which represents ~1.45% growth from its close of $112.20 on November 15.
Merck’s Stock Price Has Increased ~34% in 2018
On November 16, Merck’s stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15.
Pfizer Stock Has Risen ~20% in 2018
Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth YTD.
How Bausch Health’s Diversified Products Segment Has Performed
Bausch Health’s (BHC) Diversified segment consists of neurology, generics, dentistry, and other drugs.
How Is Salix Pharmaceuticals Positioned in November?
Bausch Health’s (BHC) wholly owned subsidiary Salix Pharmaceuticals generated revenues of $460.0 million in the third quarter compared to $452.0 million in the third quarter of 2017.
How Bausch Health’s Financials Look in November
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.
uniQure Stock Rose 35.7% Yesterday—Here’s Why
On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.
Where Jazz Pharmaceuticals’ Defitelio, Vyxeos, and Prialt Stand
Jazz Pharmaceuticals’ Defitelio generated revenues of $36.2 million in the third quarter—compared to $31.2 million in the third quarter of 2017.
Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.
Jazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.